| Symbol | CVKD |
|---|---|
| Name | CADRENAL THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 822 A1A NORTH,SUITE 306, PONTE VEDRA, Florida, 32082, United States |
| Telephone | +1 904 300-0701 |
| Fax | — |
| — | |
| Website | https://www.cadrenal.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001937993 |
| Description | Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer, more effective chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is expected to reduce adverse events such as strokes, heart attacks, and bleeds compared to warfarin, which poses challenges due to drug interactions, kidney impairment and frequent dosing adjustments. Cadrenal is focused on evaluating tecarfarins superiority to warfarin in patients for whom direct oral anticoagulants (DOACs) are not recommended in the treatment guidelines of leading cardiology associations. Tecarfarin has orphan drug and fast-track designations for LVAD and end-stage kidney disease patients with atrial fibrillation. Cadrenal is advancing a pivotal trial and pursuing clinical and commercial partnerships, with plans to study mechanical heart valve patients facing anticoagulation challenges. Additional info from NASDAQ: |
New Form ARS - Cadrenal Therapeutics, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001213900-26-084713 <b>Size:</b> 2 MB
Read moreNew Form DEF 14A - Cadrenal Therapeutics, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0001213900-26-084710 <b>Size:</b> 5 MB
Read moreCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitors Phase 3 Discontinuation
Read moreCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
Read moreNew Form PRE 14A - Cadrenal Therapeutics, Inc. <b>Filed:</b> 2026-07-23 <b>AccNo:</b> 0001213900-26-081012 <b>Size:</b> 6 MB
Read more(85% Positive) CADRENAL THERAPEUTICS, INC. (CVKD) Provides Update on conditions for its late-stage assets
Read moreCadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Read moreNew Form EFFECT - Cadrenal Therapeutics, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 9999999995-26-002367 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - Cadrenal Therapeutics, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001213900-26-079648 <b>Size:</b> 281 KB
Read more(99% Neutral) CADRENAL THERAPEUTICS, INC. (CVKD) Announces New Board Appointment
Read more